Floatz logo

Letrozole

Peritoneal Neoplasms

Swiss GO Trial GroupSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Peritoneal Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BBB
Inno-206
Eli Lilly and Company
Phase 3BBB
FLUOROURACILUM
AstraZeneca
Phase 2BB
(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE
Corcept Therapeutics
Phase 3BB
Patupilone
Novartis Pharmaceuticals
Phase 3BB

View all 44 →

Same molecule, other indications

Letrozole is also rated in:

infertility disorderDormant
BBB
Indicative ·
79 / 100
View asset →
anovulationDormant
BBB
Indicative ·
78 / 100
View asset →
Diabetes MellitusDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →